St. Jude Medical Inc. completed its acquisition of Nanostim Inc. on Oct. 14 and announced a European CE mark for the firm’s Nanostim leadless pacemaker the same day. St. Jude says it will launch the device shortly in select European countries, making it the first commercially available leadless pacemaker.
St. Jude First To Market Leadless Pacemaker With Nanostim Buy
St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.
More from Archive
More from Medtech Insight
• By
An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.
• By
“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.
• By
Reimagine Care teamed up with MedStar Health to support cancer patients at home via an AI assistant and clinical support. Reimagine Care’s data suggests its platform can save cancer centers up to $1m annually per full-time oncologist panel and reduce ED visits by 30%.